TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07767474: A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

Sponsor: Antares Therapeutics, Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 343 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07767474 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07767474 Rescue Dossier →